Mersen SA MRN

Charenton-le-Pont, 29 September 2026 Availability of the half-year financial report The Board of Directors of Marie Brizard Wine & Spirits approved the financial statements for the first half of 2026 at its meeting on 23 September 2026. The half-year financial report includes a half-year activity report, the consolidated half-year financial statements, the statutory auditors' report on the half-year financial statements and a statement by the person responsible for the half-year financial report

SAN DIEGO, September 29, 2026--Vividion announces publication of first peer-reviewed clinical data from Phase 1 study of VVD-214, investigational oral inhibitor of WRN.

Bayer (XTRA:BAYN) said the U.S. FDA has accepted a supplemental New Drug Application for Lynkuet (elinzanetant) for review. The filing covers moderate to severe vasomotor symptoms in women receiving endocrine therapy for hormone receptor-positive breast cancer. The FDA granted priority review status, indicating an accelerated assessment timeline compared with a standard review process. The priority review for Lynkuet in endocrine therapy related vasomotor symptoms is only one part of the...